Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

PortugalBack to Portugal

Clinical trials in Lisbon – page 33

638 clinical trials in Lisbon, Portugal across 3 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

PortugalOur site in PortugalEnsaios-Clinicos.pt(opens in a new tab)
Lisbon at a glance
638
clinical trials
  • Research sites3
Type of trial
Recruitment status
Quick filters

638 trials in Lisbon

Open in trial search

Multiple sclerosis relapse

Not recruiting

Study on Long-Term Safety and Effectiveness of Ofatumumab for Patients with Relapsing Multiple Sclerosis

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years
  • Substances:Ofatumumab
  • Sponsor:Novartis Pharma AG

Giant cell arteritis

Not recruiting

Study on the Safety and Effectiveness of Upadacitinib and Prednisolone in Patients with Giant Cell Arteritis

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Prednisolone
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Adenocarcinoma gastric

Not recruiting

Study of Zolbetuximab and CAPOX for Patients with Advanced Gastric or Gastroesophageal Junction Cancer

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:Astellas Pharma Global Development Inc.

Plasma cell myeloma

Not recruiting

Study comparing iberdomide, daratumumab and dexamethasone versus daratumumab, bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Celgene Corp.

Pulmonary arterial hypertension

Not recruiting

Study Comparing the Effectiveness and Safety of Macitentan 75 mg and 10 mg for Patients with Pulmonary Arterial Hypertension

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Macitentan
  • Sponsor:Actelion Pharmaceuticals Ltd.

Colorectal cancer metastatic

Not recruiting

Study Comparing XL092 and Atezolizumab with Regorafenib for Patients with Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Exelixis Inc.

Renal cancer metastatic

Not recruiting

Study of Subcutaneous Nivolumab for Patients with Previously Treated Advanced or Metastatic Clear Cell Kidney Cancer

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

CDKL5 deficiency disorder

Not recruiting

Study on the Effectiveness and Safety of Fenfluramine Hydrochloride for Patients with CDKL5 Deficiency Disorder

Registered drug
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years
  • Substances:Fenfluramine Hydrochloride
  • Sponsor:Zogenix International Limited

Type 2 diabetes mellitus+1

Not recruiting

Study comparing semaglutide with insulin glargine in overweight adults with type 2 diabetes: effectiveness of combined treatment versus insulin alone

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Insulin Glargine
  • Sponsor:Novo Nordisk A/S

Diabetic retinopathy+1

Not recruiting

Study on the Effectiveness and Safety of BAY 3283142 in Reducing Urine Albumin for Patients with Chronic Kidney Disease

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Bay 3283142
  • Sponsor:Bayer AG

Familial hypertriglyceridaemia+1

Not recruiting

Study on the Effects of ISIS 678354 in Patients with Familial Chylomicronemia Syndrome (FCS)

InvestigationalNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Isis 678354 Sodium Salt
  • Sponsor:Ionis Pharmaceuticals Inc.

Idiopathic inflammatory myopathy

Not recruiting

Study on the Effects and Safety of Efgartigimod PH20 SC for Adults with Active Idiopathic Inflammatory Myopathy

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

Other cities in Portugal

The busiest research cities in the country

All 48 cities in Portugal

Clinical research in Lisbon

What the registry says about research in the country

01 Oncology Research

Innovative trials focusing on head and neck cancer treatments and advanced lung cancer therapies, combining novel approaches with standard treatments.

  • Head & Neck Squamous Cell Carcinoma
  • Mantle Cell Lymphoma
  • Non-small Cell Lung Cancer

Studies evaluate targeted therapies and immunotherapy combinations to improve patient outcomes.

02 Autoimmune Conditions

Comprehensive research into various autoimmune disorders, with particular focus on psoriasis and systemic sclerosis treatments.

  • Psoriatic Arthritis
  • Sjögren's Syndrome
  • Plaque Psoriasis

Testing innovative biological therapies and novel treatment approaches.

03 Neurological Disorders

Studies examining treatments for Dravet Syndrome and Alzheimer's-related psychosis, focusing on improving patient quality of life.

  • Alzheimer's Disease Psychosis
  • Epilepsy Conditions

Investigating new therapeutic options for challenging neurological conditions.

04 Inflammatory Diseases

Research targeting Crohn's Disease and various inflammatory conditions, evaluating new treatment combinations.

  • Pyoderma Gangrenosum
  • Chronic Rhinosinusitis
  • Hidradenitis Suppurativa

Testing advanced therapies for chronic inflammatory conditions.

Back to PortugalAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.